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The immune response requires major changes to metabolic processes, and indeed, energy metabolism and
functional activation are fully integrated in immune cells to determine their ability to divide, differentiate, and
carry out effector functions. Immune cell metabolism has therefore become an attractive target area for ther-
apeutic purposes. A neglected aspect in the translation of immunometabolism is the critical connection
between systemic and cellular metabolism. Here, we discuss the importance of understanding and manipu-
lating the integration of systemic and immune cell metabolism through in-depth analysis of immune cell
phenotype and function in humanmetabolic diseases and, in parallel, of the effects of conventional metabolic
drugs on immune cell differentiation and function. We examine how the recent identification of selective
metabolic programs operating in distinct immune cell subsets and functions has the potential to deliver tools
for cell- and function-specific immunometabolic targeting.Introduction
The metabolic state of immune cells and its dynamic changes
during homeostasis and inflammation have become the focus
of intense investigation, as was highlighted in excellent reviews
elsewhere (MacIver et al., 2013; O’Neill andHardie, 2013; Pearce
and Pearce, 2013; Pollizzi and Powell, 2014; Wang and Green,
2012). Two critical aspects that are key to the potential therapeu-
tic manipulation of immunometabolism have emerged from
these studies. First, different immune cell functions are associ-
ated with distinct metabolic configurations: resting immune cells
utilize energetically efficient processes such as the tricarboxylic
acid (TCA) cycle, linked to the generation of ATP via oxidative
phosphorylation (OXPHOS) (Pearce and Pearce, 2013). Upon
activation, interferon-g (IFN-g)-stimulated macrophages (M1
spectrum) and antigen-activated T cells rapidly shift to aerobic
glycolysis (MacIver et al., 2013), whereas both interleukin-4
(IL-4)-stimulated macrophages (M2 spectrum) and induced reg-
ulatory T (iTreg) cells rely on oxidative phosphorylation (MacIver
et al., 2013).
Second, the metabolic status of immune cells can undergo re-
programming, which in turn can lead to changes in their func-
tional properties. When glycolysis is inhibited by modulation of
key enzymes such as pyruvate kinase M2 (PKM2) (Palsson-
McDermott et al., 2015), macrophages undergo a shift toward
a more M2-like state in terms of gene expression and boost,for example, IL-10 production. A similar effect is observed in T
helper 17 (Th17) cells, which become more like Treg cells if
glycolysis is inhibited with 2-deoxyglucose or if hypoxia-induc-
ible factor-1a (HIF-1a) is ablated (Shi et al., 2011). This plasticity
is of particular interest because it paves the way toward the
metabolic reprogramming of immune cells from an inflammatory
phenotype to an anti-inflammatory or immunomodulatory one
or vice versa (as a strategy to boost antitumor immunity, for
instance).
Although much is known about the metabolic configuration of
immune cells, the effect of systemic metabolism on immune cell
function and metabolic status has not been systematically
explored. On the basis of nutrient supply and under the influence
of the gut microbiota, metabolic organs (liver, pancreas, kidney,
gut, and adipose tissue [AT]) can divert metabolites to alternative
routes, thus defining systemic metabolic responses. These in
turn can profoundly affect immune cell function both indirectly
by regulating nutrient availability and directly by delivering
signaling metabolites. Studying immune function in genetic dis-
orders associated with insulin resistance, dyslipidemia, and
obesity can provide a tool for understanding the connection be-
tween immunity and metabolism. Similarly, ‘‘in-depth’’ analysis
of the effect of extrinsic modulators of systemic metabolism—
such as conventional metabolic drugs or products of the gut
microbiota—on immune parameters can offer further importantImmunity 43, September 15, 2015 ª2015 Elsevier Inc. 421
Figure 1. Systemic to Cellular
Immunometabolic Crosstalk
Systemic metabolism, which is affected by the diet
and gut microbiota, can contribute to immune
system homeostasis by affecting the immune cell
metabolic setup via nutrient availability and active
metabolite-induced signaling, thus regulating their
differentiation (1). Reprogramming of themetabolic
configuration of immune cells can occur via
epigenetic events also influenced by the metabolic
microenvironment (2), thus opening a window of
opportunity for therapeutic manipulation. Alter-
ation of systemic metabolism due to dietetic
overload or genetic defects (3) is associated with
altered immune cell metabolism and the develop-
ment of chronic inflammation and ineffective
immunity (4).
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changes. In addition, novel metabolic features and meta-
bolism-regulated functions in immune cells have recently been
identified and could be targeted therapeutically by modification
of systemic metabolism.
The Crosstalk between Systemic Metabolism and
ImmuneCells: Lessons fromHumanMetabolic Diseases
In humans, hyperlipidemia (both hypercholesterolemia and hy-
pertrygliceridemia), diabetes, obesity, and non-alcoholic fatty-
liver disease (NAFLD), as well as alterations in the gutmicrobiota,
are often associated with metabolism-related impaired immune
functions. Therefore, they provide a powerful ‘‘in vivo’’ working
model for investigating the interplay between systemic and im-
mune cell metabolism (Figure 1).
Hyperlipidemia
Primary (genetic) or acquired hyperlipidemias are characterized
by increased plasma levels of cholesterol and/or triglycerides
(TGs) and of the lipoproteins carrying these lipids. Classically,
hypercholesterolaemia has been associated with cholesterol
accumulation in macrophages and other immune cells and re-
sults in atheroma formation and the development of atheroscle-
rosis. More recently, this event has been associated with direct
activation of pro-inflammatory cascades, including Toll-like re-
ceptor (TLR) (Erridge, 2010) and inflammasome activation
(Sheedy et al., 2013). However, the net effect of this process is
debated, given that binding of TLRs by modified lipoproteins
has been shown to suppress the downstream pro-inflammatory
cytokine response (Kannan et al., 2012).
Do the effects of hyperlipidemia extend beyond the relatively
well-defined immune events in atherogenesis? During infection,
significant changes in lipid and lipoprotein metabolism are
observed: lipopolysaccharides (LPSs) and pro-inflammatory cy-
tokines induce de novo production of free fatty acids, thus favor-
ing a combination of TG synthesis in the liver and a reduction of
TG hydrolysis. This then results in reduced clearance of very-422 Immunity 43, September 15, 2015 ª2015 Elsevier Inc.low-density lipoproteins (VLDLs) and
increased TG levels (Wendel et al.,
2007). In addition, the increase in free fatty
acids induces insulin resistance, thus
contributing to increased glucose levels
during systemic inflammation. In contrast,levels of high-density lipoprotein cholesterol (HDL-C) and low-
density lipoprotein cholesterol (LDL-C) decrease during sepsis
mainly as a consequence of lipoprotein removal from the liver,
which is implicated in the clearance of lipids from pathogens (Pi-
rillo et al., 2015). Studies in animal models and in humans have
shown that conditions leading to reduced lipoprotein removal
and hypercholesterolaemia are associated with deteriorated
septic shock outcome (Walley et al., 2014). Similarly, a low
plasma HDL-C level (associated with a low plasma apoA-I level)
is a poor prognostic factor for severe sepsis, given that it is asso-
ciated with increased mortality and adverse clinical outcomes
(Chien et al., 2005).
In turn, bacterial infections affect lipid and lipoprotein meta-
bolism as a result of reduced reverse cholesterol transport and
excretion (Castrillo et al., 2003; Gillespie et al., 2015). Under
these conditions, the balance between systemic and cellular
lipid homeostasis is tightly controlled at the cellular level by
different key transcription factors, such as sterol regulatory
element binding protein (SREBP), liver X receptor (LXR), and
peroxisome proliferator-activated receptors (PPARs), which
modulate genes that affect lipid biosynthesis or intake, cellular
lipid excretion, and lipoprotein synthesis and catabolism and
thus represent important targets for immunometabolic regula-
tion (see below).
In humans, although hyperlipidemia has no effect on Treg cells
(Ammirati et al., 2010), it is associated with increased T effector
cell memory polarization (Ammirati et al., 2012). Genetically
determined conditions with low HDL-C levels and impaired
cholesterol efflux in humans are associated with increased clas-
sical CD14+CD16 monocytes (Sala et al., 2013). In addition,
hyperlipidemia can affect the immune system through an
enhanced bone marrow and extramedullary myelopoiesis. For
instance, the increased cholesterol content in the plasma mem-
brane upholds the expression and function of the receptors to
IL-3, IL-5, and GM-CSF, thus favoring the proliferative response
of hematopoietic stem cells (Yvan-Charvet et al., 2010).
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ing to dyslipidemia? To date, genetic conditions associated with
extreme hyperlipidemic phenotypes include familial hypercho-
lesterolaemia (FH), which, because of the defective liver catabo-
lism, results in extremely elevated plasma levels of LDL-C and
favors atherosclerotic processes (Sniderman et al., 2014); and
familial chylomicronemia syndrome (FCS), which is the conse-
quence of a delay in the catabolism of TG-rich lipoproteins and
results in extremely elevated plasma TG levels (Tremblay et al.,
2011). Homozygous and heterozygous FH patients are at a
very elevated risk of premature death due to myocardial infarc-
tion within the first two decades of life (Sniderman et al., 2014),
whereas FCS results in recurrent acute pancreatitis (Tremblay
et al., 2011).
These extreme metabolic disorders lead to a flux of lipid nutri-
ents in the circulation and might therefore be conditions where
the interplay between systemic and cellular metabolism on im-
mune cells can be addressed. Despite the fact that changes in
immune cell subsets have been described in relation to plasma
lipids and lipoproteins levels (Ammirati et al., 2010, 2012), there
are no data available on the metabolic immune cell setting in
these patients. However, it has to be borne in mind that lifelong
metabolic impairment in these patients could trigger adaptation
mechanisms; in other words, the potential effect of drugs modu-
lating metabolic responses on immune cells in these patients
might be different from that observed in patients with immune
diseases.
Obesity, Diabetes, and NAFLD
Obesity predisposes to insulin resistance, diabetes, NAFLD, and
atherosclerosis (Kahn et al., 2006). The transition of obese sub-
jects frommetabolic health tometabolic dysregulation is thought
to be catalyzed by chronic low-grade inflammation in metabolic
organs, to which a multitude of immune cells contribute (Chatzi-
georgiou and Chavakis, 2015; Chatzigeorgiou et al., 2012; Ip
et al., 2015; Osborn and Olefsky, 2012). In the AT and liver, mul-
tiple close interactions between immune cells and parenchymal
cells (adipocytes and hepatocytes) might contribute to meta-
bolic homeostasis and metabolic dysfunction in the lean and
obese state, respectively (Chatzigeorgiou and Chavakis, 2015).
Type 2 immunity predominates in the lean AT, whereby eosin-
ophils, M2-like macrophages, or type 2 innate lymphoid cells
(and the cytokines they produce, such as IL-4) promote not
only an anti-inflammatory environment but also homeostatic
functions of the AT, such as thermogenesis and energy dissipa-
tion via a process termed ‘‘beige’’ adipogenesis (white adipo-
cytes with ‘‘brown-like’’ properties) (Brestoff et al., 2015; Chatzi-
georgiou and Chavakis, 2015; Harms and Seale, 2013; Osborn
and Olefsky, 2012; Qiu et al., 2014; Wu et al., 2011). In contrast,
increased energy storage in the expanding AT in obesity might
promote adipocyte dysfunction and a pro-inflammatory milieu
with enhanced abundance of CD8+ T cells and M1-polarized
pro-inflammatory macrophages, which are thought to trigger in-
sulin resistance (Chatzigeorgiou and Chavakis, 2015; Chatzi-
georgiou et al., 2014b; Ip et al., 2015; Lumeng et al., 2007; Ma-
this, 2013; Nishimura et al., 2009; Osborn and Olefsky, 2012).
Several overlapping and interdependent mechanisms, including
relative hypoxia of the expanding AT and activation of the endo-
plasmic reticulum (ER) stress response, have been proposed to
contribute to obese AT dysfunction and thereby inflammation(Chmelar et al., 2013; Hotamisligil, 2010; Ichiki and Sunagawa,
2014). Furthermore, the enhanced abundance of fatty acids in
obesity might directly promote AT inflammation in a TLR4-
dependent manner (Shi et al., 2006).
Interestingly, obesity might trigger not only recruitment but
also local proliferation of AT macrophages in a manner depen-
dent on the chemokine MCP-1 (Amano et al., 2014). At the
same time, the percentage of AT Treg cells shrinks with
increasing obesity (Cipolletta et al., 2012; Feuerer et al., 2009;
Mathis, 2013). The number of AT Treg cells might be regulated
by invariant natural killer T cells, which also promote an anti-in-
flammatory switch in AT macrophages (Lynch et al., 2015).
Moreover, AT Treg cell development and maintenance require
IL-33 signaling and the transcriptional regulators BATF and
IRF4 (Vasanthakumar et al., 2015), whereas IL-21 negatively reg-
ulates IRF4 and AT Treg cells (Fabrizi et al., 2014).
The inflammatory environment of the obese AT directly con-
tributes to insulin resistance. In particular, activation of immune
receptors, such as TLRs, IL-1 receptor type I (IL-1RI), and/or tu-
mor necrosis factor receptor (TNFR), results in the activation of
NF-kB and JNK signaling, which can induce serine phosphoryla-
tion of IRS-1 and IRS-2 and thereby inhibition of downstream in-
sulin signaling. It can also propagate inflammatory gene expres-
sion and lead to a positive paracrine loop, contributing further to
obesity and insulin resistance (McNelis and Olefsky, 2014).
Besides causing inflammation of the AT, obesity promotes
liver inflammation, leading to NAFLD and non-alcoholic steato-
hepatitis (NASH) (Wree et al., 2013). Obesity-related liver inflam-
mation is mediated by inflammatory activation of Kupffer cells
and infiltrated monocytes and/or macrophages (Huang et al.,
2010; Miura et al., 2012; Stienstra et al., 2010; Tosello-Trampont
et al., 2012). Additionally, cells of the adaptive immunity and NKT
cellsmight promote not only NASH and fibrosis (Sutti et al., 2014;
Syn et al., 2010) but also the progression to hepatic carcinogen-
esis (Wolf et al., 2014). Treg cells might counteract inflammation
andNASH development (Ma et al., 2007). For instance, reduction
of Treg cells in mice double deficient in the co-stimulatory mole-
cules B7.1 andB7.2 resulted in enhanced obesity-related inflam-
mation in the AT and liver and development of insulin resistance
and NASH (Chatzigeorgiou et al., 2014a). Thus, the role of
different immune cell subpopulations as modulators of meta-
bolic inflammation and insulin resistance in the AT and liver in
obesity is unequivocal.
Several studies have addressed the question of how the
cellular metabolism of immune cells and their function is shaped
by the alterations of obese metabolic organs. For instance, lipid
accumulation in AT macrophages or oxidized LDL accumulation
in Kupffer cells promotes the M1 pro-inflammatory state in both
cell types, further exacerbating obesity-related AT or liver inflam-
mation, respectively (Bieghs et al., 2013; Prieur et al., 2011). AT
macrophages contribute substantially to lipid trafficking.
Obesity-related lipid accumulation induces lysosome biogen-
esis, resulting in lipid catabolism in AT macrophages (Xu et al.,
2013). In this context, lipoprotein lipase in AT macrophages en-
hances their ability to sequester excess lipids in obesity and sup-
ports glucose tolerance (Aouadi et al., 2014). On the other hand,
macrophage-specific expression of the cholesteryl ester hydro-
lase promotes the M2 state in Kupffer cells, thereby decreasing
NAFLD (Bie et al., 2012).Immunity 43, September 15, 2015 ª2015 Elsevier Inc. 423
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ness through its ability to enhance glucose uptake, amino acid
transport, lipid metabolism, and protein synthesis (Helderman,
1981; Stentz andKitabchi, 2003). Given that insulin enhances en-
ergy and protein-synthesis requirements for appropriate T cell
functions, defects in insulin receptor signalingmight lead to inap-
propriate immune responses and chronic inflammation in meta-
bolic states such as obesity and diabetes. Insulin might support
Th2 T cell differentiation (Viardot et al., 2007), which can modu-
late inflammation. In addition, Treg cells express the insulin
receptor, and high levels of insulin via activation of the AKT-
mTOR pathway can impair the ability of Treg cells to produce
IL-10. IL-10 in turn inhibits the production of TNF by macro-
phages (Han et al., 2014).
The AT-derived hormone leptin represents one of the molecu-
lar links connecting nutritional status, AT, and T-cell-mediated
immune responses, as extensively reviewed in La Cava andMat-
arese (2004). Since its discovery in 1994, compelling experi-
mental evidence has shown that both leptin and leptin receptor
(LepR) deficiency are associated with increased susceptibility
to infections but also resistance to autoimmune diseases, such
as type 1 diabetes, multiple sclerosis (MS), and experimental co-
litis in mice (La Cava and Matarese, 2004). These effects were
linked to its capacity to boost both Th1 and Th17 cell immune re-
sponses on the one side and to restrain proliferation of Treg cells
on the other (La Cava and Matarese, 2004). Because AT Treg
cells support AT homeostasis and prevent obesity-related insulin
resistance (Cipolletta et al., 2012), the possibility that in over-
weight subjects the depletion of AT-resident Treg cells might
be linked to the capacity of leptin to constrain Treg cell prolifer-
ation should be considered (De Rosa et al., 2007).
Another major interaction between metabolism and immunity
in diabetes is the impairment of host defensemechanisms in dia-
betic patients. Epidemiological studies have shown that patients
with diabetes have a higher susceptibility to infections than do
healthy individuals (Joshi et al., 1999). Several explanations
have been proposed for this increased susceptibility to infec-
tions in diabetes patients: (1) a microbiological effect inducing
bacterial growth by hyperglycemia, (2) inhibitory effects of ketoa-
cidosis on leukocyte phagocytosis and killing of pathogens, and
(3) defective activation of cellular and/or humoral immunity due
to impaired production of proinflammatory cytokines (Delamaire
et al., 1997; Gallacher et al., 1995). This latter effect has been
supported by a study reporting a defective production of proin-
flammatory Th1 cell cytokines, such as IFN-g, in patients with
diabetes. The mechanism leading to this defect has been re-
ported to relate to defective expression of IL-18 receptors on
the lymphocyte membrane from diabetes patients and thus a
‘‘de facto IL-18 resistance’’ and decreased capacity to induce
IFN-g production (Zilverschoon et al., 2008). Because IFN-g
has long been known to be crucial for the activation of phagocy-
tosis, the release of oxygen and nitrogen radicals by neutrophils,
and increased intracellular bacterial killing (Murray, 1994), this
represents an important immune defect in patients with dia-
betes. A recent study has reported that neutrophils from diabetic
patients are more susceptible to forming extracellular traps
(NETs) as a result of increased expression of peptidylarginine de-
iminase 4, a key enzyme of chromatin decondensation (Wong
et al., 2015). Although this mechanism could be aimed at424 Immunity 43, September 15, 2015 ª2015 Elsevier Inc.improving microbial defense, it might also help in explaining
the poor wound-healing capacity of diabetic individuals.
Interestingly, in addition to a generalized immune inflamma-
tory response, activation of adaptive immunity and autoimmune
responses against pancreatic beta cells are often detected in
obese and type 2 diabetes (T2D) patients, further suggesting
the activation of aberrant immune circuits as a consequence of
metabolic overload and—possibly—increased insulin secretion
(Brooks-Worrell et al., 2013; Sarikonda et al., 2014; Winer
et al., 2011). Abnormalities of mucosal-associated invariant T
(MAIT) cells, a novel subset of innate-like T cells that recognize
bacterial ligands (Dusseaux et al., 2011; Le Bourhis et al.,
2011), have recently been described in T2D and obese patients
(Magalhaes et al., 2015). In these patients, these cells are
dramatically decreased in the circulation and accumulate in the
AT, where they display an activated, Th17-cell-like phenotype.
The alteration of this T cell subset further emphasizes the link be-
tween metabolic stress and the gut microbiota, because vitamin
B2metabolites produced by bacteria are required for generating
MAIT-cell-activating ligands (Kjer-Nielsen et al., 2012; Patel
et al., 2013).
The Gut Microbiota and Systemic Metabolism
Rising evidence suggests that variation in the gut microbiome at
the gene and species levels predisposes individuals to increased
risk of obesity-related metabolic disorders, including insulin
resistance and T2D (Delzenne et al., 2011). The composition of
the gut microbiota differs between obese and lean individuals,
between diabetic and non-diabetic patients, and between pa-
tients with and without hepatic diseases. The qualitative and
quantitative changes in the intake of specific nutrients not only
affect the composition of the gut microbiota but also can modu-
late the expression of genes in host tissues, such as the liver and
AT (Delzenne et al., 2011). This in turn might affect the fat mass
and lead to metabolic alterations associated with the gut barrier
and/or liver function and immunity. The composition of the gut
microbiota also defines the differential production of metabo-
lites, which have long been implicated in homeostatic and meta-
bolic events, including inflammatory activation, both inside and
outside the gut. The impact of these metabolites on immune
cell differentiation and function has only recently begun to be
appreciated (Dorrestein et al., 2014; Sharon et al., 2014; Thor-
burn et al., 2014).
For example, complex carbohydrates, such as dietary fibers,
are metabolized by the colonic microbiota to oligosaccharides
and monosaccharides and then fermented to short-chain fatty
acid (SCFA) end products, mainly acetate, propionate, and buty-
rate. SCFAs are absorbed in the colon, where butyrate provides
energy for colonic epithelial cells, and acetate and propionate
reach the liver and peripheral organs, where they are substrates
for gluconeogenesis and lipogenesis (Dorrestein et al., 2014;
Sharon et al., 2014; Thorburn et al., 2014).
In addition to being energy sources, SCFAs control colonic
gene expression by inhibiting the enzyme histone deacetylase
(HDAC) (Davie, 2003) and exert metabolic regulation by signaling
through G-protein-coupled receptors (GPCRs) (Tan et al., 2014).
Probably the best-characterized metabolite-sensing GPCRs are
GPR43 and GPR109A, which bind SCFAs. GPR43 and
GPR109A appear to be important for gut homeostasis, and
both are expressed by the colonic epithelium, by inflammatory
Figure 2. The Molecular and Translational
Basis of Immunometabolism
The profound integration of systemic and cellular
metabolism suggests that therapeutic manipula-
tion of systemic metabolism could re-establish
immune homeostasis. The main challenge in
translational immunometabolism is the identifica-
tion of selective metabolic alterations in patho-
genic immune cells and the definition of the mo-
lecular pathways selectively engaged by
homeostatic metabolic immune cell phenotypes
(effector versus regulatory) as an end point of
immunometabolic therapies. Effective strategies
might involve the following: (1) repositioning of
existing (‘‘old’’) metabolic drugs, which, by
improving homeostasis of metabolic organs (liver,
adipose tissue, and pancreas), can divert metab-
olites to alternative routes and thus define sys-
temic and cellular metabolic responses; and (2)
reprogramming immune cells via epigenetic
events and/or via the control of the metabolite
milieu, as well as via modulating metabolic-
dependent immune cell trafficking.
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cells. Regulation of colonic and peripheral Treg cell numbers re-
lies upon the expression of these metabolite-sensing receptors
by colonic macrophages and DCs, which promote Treg cell dif-
ferentiation (Furusawa et al., 2013; Singh et al., 2014; Smith
et al., 2013). Further, butyrate has been shown to promote the ex-
trathymic induction of Treg cells via the intronic enhancer CNS1
(conserved non-coding sequence 1) (Arpaia et al., 2013). This ef-
fect was potentiated by propionate capable of HDAC inhibition.
Signaling through these receptors also affects other immune
functions depending on the cellular type. For example, SCFAs
suppress inflammation throughGPR43 signaling in immunecells,
such as neutrophils (Maslowski et al., 2009; Sina et al., 2009).
GPR109A binds the SCFA butyrate but also the tryptophan
metabolite nicotinic acid. Nicotinic acid is currently used inmeta-
bolic diseases todecrease plasmaTGand increaseHDL-C levels
(Remaley et al., 2014). All of the metabolite-sensing GPCRs are
expressed by immune cells, particularly by innate-type cells
(Thorburn et al., 2014). They are also expressed on the intestinal
epithelium, which probably relates to roles in maintenance of
epithelial integrity, and by metabolism-related tissues or cells,
for instance, pancreatic islets or white AT (Thorburn et al.,
2014). The role of many of these receptors is poorly defined.
Given that many specialized metabolites isolated from other mi-
crobes, such as rapamycin, are now in clinical use to control im-
mune-mediated diseases and that changes in the gut microbiota
can be reversed by dieting and relatedweight loss,metagenomic
and integrative metabolomic approaches could help elucidate
whichbacteria in the humangut, ormore specificallywhich active
metabolitesor geneactivities, contribute to thecontrol of host en-
ergy metabolism and pave the way to a myriad of novel and tar-
geted approaches for immunomodulation.
Metabolism-Targeting Drugs and Immune Function
Several drugs that are currently used in clinic for patients with
diabetes, dyslipidemia, and metabolic dysfunctions have beenshown to affect immune cell function. By providing information
on the overall effect of systemically targeting a given metabolic
pathway, a ‘‘retrospective’’ analysis can provide a human exper-
imental model of how systemic and cellular metabolism integrate
to have an impact on immune cells, as well as a molecular basis
for the repositioning of ‘‘old’’ drugs as immunomodulators
(Figure 2).
Targeting AMPK
Metformin (dimethylbiguanide) is a metabolic drug that is widely
prescribed for T2D because of its ability to improve insulin sensi-
tivity. Metformin activates AMP-activated protein kinase (AMPK)
(Shaw et al., 2005) and reduces redox shuttle enzyme mitochon-
drial glycerophosphate dehydrogenase (Madiraju et al., 2014).
Metformin has effects beyond those on glucose metabolism
and decreases plasma inflammatory markers, including soluble
intercellular adhesion molecule, vascular cell adhesion molecule
1, macrophage migration inhibitory factor, and C-reactive pro-
tein (Caballero et al., 2004; Dandona et al., 2004). As underlined
above, an upregulated glycolysis, even in the absence of hypoxia
(aerobic glycolysis, or the so-called ‘‘Warburg effect’’), has been
shown to be a feature of activated immune cells (O’Neill and Har-
die, 2013). Activation of glycolysis is under the control of mTOR
(Yang and Chi, 2012), andmetformin inhibits mTOR through acti-
vation of AMPK (Isoda et al., 2006). Inhibition of the Akt-mTOR
pathway by metformin has been also shown to inhibit the induc-
tion of trained immunity and the protection against reinfection
induced by beta-glucans (Cheng et al., 2014).
A non-canonical AMPK-mediated pathway has recently been
implicated in the regulation of T cell senescence. Cellular senes-
cence is defined as the irreversible loss of proliferative capacity
despite continued viability and metabolic activity (Campisi and
d’Adda di Fagagna, 2007). This phenotype arises as a conse-
quence of either telomere erosion or DNA damage by reactive
oxygen species (ROS) or the activation of cellular-stress path-
ways (Campisi and d’Adda di Fagagna, 2007; Passos and Von
Zglinicki, 2006). T cell senescence is thought to contribute toImmunity 43, September 15, 2015 ª2015 Elsevier Inc. 425
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Reviewthe decline of immune function in old age, and a larger proportion
of senescent T cells are commonly observed in the elderly and in
patients with chronic viral infections and those with autoimmune
disorders (Henson and Akbar, 2010). Senescent T cells in hu-
mans are characterized by the re-expression of the naive T cell
marker CD45RA, loss of CD28 and CD27 expression, poor pro-
liferative responses, and the shortest telomeres (Coppe´ et al.,
2008; Henson and Akbar, 2010). Far from being inert, senescent
T cells exhibit potent effector functions, secrete high levels of
both TNF-a and IFN-g, and display potent cytotoxic activity
(Coppe´ et al., 2008; Henson and Akbar, 2010; Henson et al.,
2014), for which they require active metabolism. CD8+ effector
memory T cells that re-express the naive T cell marker
CD45RA have many characteristics of cellular senescence,
including decreased proliferation, defective mitochondrial func-
tion, and elevated levels of both ROS and p38 MAPK (Coppe´
et al., 2008; Henson and Akbar, 2010; Henson et al., 2014). Inhi-
bition of p38 MAPK signaling in senescent CD8+ T cells
increased their proliferation, telomerase activity, mitochondrial
biogenesis, and fitness (Henson et al., 2014); this effect was
the consequence of increased autophagy independent of
mTOR activation and was the result of enhanced interaction be-
tween p38 interacting protein (p38IP) and autophagy protein 9
(ATG9) (Henson et al., 2014).
Further, in senescent T cells, p38 is not activated by canonical
MAPK signaling or by T cell antigen receptor (TCR) signals (alter-
native pathway) (Chang and Karin, 2001), which are defective in
these cells. Instead, senescent human T cells engage a distinct
mechanism whereby the intracellular metabolic sensor AMPK
triggers autophosphorylation of p38 via the scaffold protein
TAB1 (Lanna et al., 2014). Activation of p38 through AMPK-
TAB1 was induced by endogenous DNA damage and by a
decrease in intracellular concentrations of glucose (defined as
the ‘‘intrasensory’’ pathway) (Lanna et al., 2014). Once triggered,
this pathway inhibits T cell proliferation and telomerase activa-
tion via p38 signaling, and this can be reversed by inhibition of
AMPK, TAB1, or p38 itself (Lanna et al., 2014).
The effect of metformin on immune function opens the possi-
bility of novel therapeutic applications for this drug. Recent
epidemiological studies have suggested that metformin has an
unexpected anticancer effect, and metformin is currently in clin-
ical trials for several major cancer types (Viollet et al., 2012).
Moreover, the anti-inflammatory effects of metformin open the
possibility of its therapeutic use in chronic inflammatory and
autoimmune diseases, as one recent study has suggested for
systemic lupus erythematosus (SLE) (Yin et al., 2015). Even
more exciting, the combination of potentiating effects on antimy-
cobacterial capacity of leukocytes and the dampening of inflam-
mation has recently implicated metformin as a novel adjuvant
therapy in tuberculosis (Singhal et al., 2014).
Targeting Cholesterol and Fatty-Acid Metabolism
Lipid content and metabolism in immune cells have to be criti-
cally balanced; although the pro-inflammatory effect of choles-
terol intake by immune cells contributes to diseases associated
with chronic metabolic inflammation, including atherosclerosis
and obesity, the promotion of inflammatory responses probably
has beneficial effects in the response to infections. Activated
T cells take advantage of the Warburg effect to funnel acetyl-
CoA into mevalonate and fatty-acid-synthesis pathways. The426 Immunity 43, September 15, 2015 ª2015 Elsevier Inc.first is involved not only in steroid synthesis but also in isopreny-
lation, a key process for the plasma membrane attachment of
small GTPases, such as Ras, that are critically involved in
T cell function (Thurnher and Gruenbacher, 2015). Cell-intrinsic
lysosomal lipolysis is critical in macrophage M2 activation
(Huang et al., 2014) and contributes to enhance CD8+ T cell
memory (O’Sullivan et al., 2014).
All these observations point to a critical role for the
transcription factors modulating the availability of intracellular
cholesterol and fatty acids: SREBP controls genes that regulate
cholesterol biosynthesis and uptake, and it is activated by
low cholesterol levels, whereas LXR is activated by oxysterols
(oxidative metabolites of cholesterol), which signal excess intra-
cellular cholesterol content and prompt the elimination (Spann
and Glass, 2013). This is achieved mainly through the induction
of the expression of the ATP-binding cassette (ABC) trans-
porters, which mediate the reverse cholesterol transport to the
liver (Tall and Yvan-Charvet, 2015). Importantly, cholesterol
serves as an essential component of the membranes and is crit-
ical for the formation of lipid rafts, membrane microdomains that
promote the assembly of signaling receptors (Catapano et al.,
2014). Thus, cholesterol removal from cellsmight alter the forma-
tion of lipid rafts and the organization or signaling of TLRs and
other immune receptors (Koseki et al., 2007). Direct functional
studies have substantiated the cross-interference between
cholesterol transport and TLR signaling by showing that the
absence of ABC transporters favors the bactericidal functions
of macrophages (Zhu et al., 2012), possibly through both
enhanced function of TLR2, TLR3, and TLR4 and inflammasome
activation by cholesterol crystals (Yvan-Charvet et al., 2008).
However, this hypothesis has recently been challenged by a
report showing that cholesterol depletion of human and mouse
macrophages does not influence TLR signaling but instead ex-
erts broad anti-inflammatory effects by upregulating the tran-
scriptional repressor ATF3 and modulation of gene transcription
(De Nardo et al., 2014).
Activation of LXR also drives the incorporation of polyunsatu-
rated fatty acids into phospholipids through the induction of the
remodeling enzyme Lpcat3. In turn, Lpcat3 activity ameliorates
ER stress induced by saturated free fatty acids in vitro or by he-
patic lipid accumulation in vivo, thus providing an endogenous
mechanism for the preservation of membrane homeostasis dur-
ing lipid stress and inflammation (Rong et al., 2013). This finding
reinforces the concept that modulation of cellular lipid composi-
tion critically affects inflammatory responses.
Indeed, extracellular acceptors of cholesterol, such as high-
density lipoproteins, contribute to the modulation of immune cell
function (Norata et al., 2012) and connect cellular and systemic
lipid metabolism by depleting cells of cholesterol and phospho-
lipids (Tall and Yvan-Charvet, 2015; Zhao et al., 2012). This tight
equilibrium has to be taken into account when pharmacological
targeting of lipid metabolism in immune cells is considered.
Besides this caveat, pharmacological inhibition of cholesterol
synthesis is to date the most successful example of how target-
ing systemic metabolism can reprogram immune cell function
toward homeostasis. Statins, inhibitors of the enzyme 3-hy-
droxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase
(which catalyzes the formation of mevalonate, the rate-limiting
step for cholesterol synthesis), are the most efficient and widely
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compounds are endowed with dual functions. Originally de-
signed to target elevated plasma lipid levels, the ‘‘traditional’’
cause of atherosclerosis, statins might also confer cardiovascu-
lar benefit by modulating the inflammatory component of this
disease. Indeed, beyond lowering plasma lipids, some statins
provide a cardiovascular benefit that most likely relies on their
capacity to diminish levels of many inflammatory markers (Tou-
soulis et al., 2014). In the presence of statins, cells that partici-
pate in atherosclerosis (endothelial cells, smooth-muscle cells,
monocytes or macrophages, and T lymphocytes) display dimin-
ished pro-inflammatory functions in in vitro assays (Scho¨nbeck
and Libby, 2004). For instance, monocytes express fewer integ-
rins and adhesion receptors, and endothelial cells decrease their
synthesis of cell-adhesion molecules, and in both cell types, sta-
tins can inhibit the IFN-g-inducedMHCII expression (Kwak et al.,
2000).
Some of these effects have been clearly shown to be indepen-
dent of the HMG-CoA reductase functions of statins (Aktas et al.,
2003;Weitz-Schmidt et al., 2001). On the other side, the reported
effect of statins on the production of chemokines (Diomede et al.,
2001), as well as many of their non-lipid-lowering effects, seems
to depend, at least in part, on the biosynthesis of isoprenoids
(and downstream prenylated proteins) arising from mevalonate;
these isoprenoids critically determine Th1 from Th2 cell fate in
pathogenic T cells (Dunn et al., 2006). Indeed, statins simulta-
neously alter several signaling pathways of immune cells
because (1) isoprenoid intermediates serve as important lipid at-
tachments for a variety of proteins (including the small guanosine
triphosphate binding proteins) and (2) protein isoprenylation is
implicated in intracellular signaling events. As an illustration of
their potential impact through these pathways, it has been
shown that statins can deviate T cell differentiation toward the
generation of Treg cells instead of pro-inflammatory Th17 cells
via a mechanism dependent on protein geranylation (Kagami
et al., 2009; Kim et al., 2010).
Not only isoprenoids but also sterols were shown to critically
affect T cell differentiation. Initially, it was reported that Treg cells
require lipid and cholesterol metabolism and that themevalonate
pathway is particularly important for coordinating Treg cell
proliferation and for upregulating the suppressive molecules
CTLA-4 and ICOS to establish Treg cell functional competency
(Zeng et al., 2013). Upregulated lipid biosynthesis via the meval-
onate pathway andmTORwas shown to promote the expression
of effector molecules and the immunosuppressive activity of
Treg cells. However, two recent works seem to contradict this
finding (Hu et al., 2015; Santori et al., 2015); indeed, programs
for cholesterol biosynthesis and uptake are induced during
Th17 cell differentiation along with a concomitant suppression
of cholesterol metabolism and efflux. More importantly, a pre-
cursor of cholesterol, namely desmosterol, functions as a potent
endogenous RORg agonist, thus orchestrating Th17 cell differ-
entiation. Finally, inhibition of cholesterol synthesis prevents
Th17 cell differentiation (Hu et al., 2015; Santori et al., 2015).
How does one explain these contrasting findings? First, it is
possible that a number of cholesterol precursors and metabo-
lites might possess dual activities—promoting both LXR and
SREBP activation—in order to balance cholesterol homeostasis.
Alternatively, they might be rapidly metabolized to compoundswith activity opposing that of their precursor (Spann and Glass,
2013). It is tempting to speculate that, under physiological con-
ditions, a similar mechanism might occur in immune cells to
prevent excessive polarization toward a specific phenotype
(yin-yang response); whether an impairment of this intracellular
balance occurs under pathological conditions remains to be
explored. Second, statin effects in vitro are largely dependent
on the dose used (in many cases supraphysiological) and the
type of statin. Indeed, not all compounds share the anti-inflam-
matory properties, and some, such as simvastatin or lovastatin,
are prodrugs, which need to be converted to active metabolites
(Mauro, 1993). This process occurs in vivo, but not in vitro, and
questions the relevance of data obtained from incubating cells
with simvastatin and not with the active hydroxy acid metabolite.
Finally, whereas statins effectively control cholesterol and iso-
prenoid biosynthesis in vitro, in vivo they are prevalently distrib-
uted in the liver (Reinoso et al., 2002), and it is less likely that they
could inhibit HMGCoA reductase in immune cells to a large
extent. All these aspects suggest that the effect of statins on im-
mune cells observed in vitro might not fully translate in physio-
logical settings. Thus, although statins improve disease activity
and the inflammation factor in patients with rheumatoid arthritis
(Lv et al., 2015), MS (Chataway et al., 2014), and SLE (Ulivieri and
Baldari, 2014), it remains to be addressed whether the immuno-
modulatory effects of statins in vivo are the consequence of a
systemic reduction of cholesterol levels or arise from a direct
metabolic effect in immune cells, or both.
The activation of PPARs also plays a key role in immunometa-
bolic regulation. PPARs are nuclear receptors that regulate gene
transcription. PPAR-a is highly expressed in liver and skeletal
muscle, controls genes involved in fatty-acid oxidation (FAO),
and plays a pivotal role in energy homeostasis and lipoprotein
metabolism by inducing lipoprotein lipase and apoA-I expres-
sion (Duval et al., 2007). PPAR-g is highly expressed in adipo-
cytes, in addition to skeletal muscle, liver, and kidney, and has
been shown to regulate the expression of genes that mediate
adipocyte differentiation, energy metabolism, and insulin action
(Lefterova et al., 2014). PPAR agonists were originally designed
to normalize metabolic disturbances; later, targeting these nu-
clear receptors revealed unexpected effects on the inflammatory
response during metabolic diseases. PPAR-a mostly displays
anti-inflammatory properties in the context of liver inflammation
by directly targeting hepatocytes and Kupffer cells (Stienstra
et al., 2007), although important effects were also reported in
endothelial cells (Mandard and Patsouris, 2013). Furthermore,
PPAR-a activators display significant trans-repressional activ-
ities on inflammatory genes by interfering with STAT, AP-1,
NF-kB, and NFAT and directly induce the expression of IL-1
receptor antagonist (Mandard and Patsouris, 2013). Finally,
PPAR-a activators such as fibrates were shown to shift the cyto-
kinesecretionof humanTcell linesby inhibiting IFN-gandpromot-
ing IL-4 secretion (Lovett-Racke et al., 2004; Marx et al., 2004).
PPAR-g plays a pivotal role in AT biology by favoring the alter-
native activation of macrophages (Odegaard et al., 2007) and
also facilitating lipid metabolism in metabolically activated mac-
rophages (Kratz et al., 2014). PPAR-g expression by visceral AT-
resident Treg cells is instrumental for their ability to control the
inflammatory state of AT and thereby insulin sensitivity (Cipol-
letta et al., 2012). Thiazolidinedione and other PPAR-g agonistsImmunity 43, September 15, 2015 ª2015 Elsevier Inc. 427
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obese mice (Cipolletta et al., 2012). Interestingly, PPAR-g and
its Ser273 phosphorylation play a crucial role in AT Treg cell
numbers and function (Cipolletta et al., 2012; Cipolletta et al.,
2015). Beneficial effects of PPARs’ activation were reported in
other conditions, including inflammatory bowel disease, CNS
inflammation, and LPS-induced cardiac and pulmonary inflam-
mation (Mandard and Patsouris, 2013).
In summary, PPAR agonists could become an attractive drug
candidate for anti-inflammatory therapies. Although only a small
number of anti-inflammatory genes have been identified as
direct and classical PPAR targets with a functional PPAR
response element in genomic DNA, mechanisms involved in
the anti-inflammatory properties of PPARs are broader than
what might have been thought originally. Furthermore, given
that several genes involved in TG metabolism are targeted by
PPARs and these appear to be critical for alterative activation
of macrophages (Huang et al., 2014), data from clinical trials ad-
dressing the impact of PPAR-a and PPAR-g agonists on immu-
nometabolic disorders will be pivotal for translating the beneficial
effects of these drugs in the clinical immunological setting.
Targeting the mTOR Pathway
It has become clear that in vivo, the modulation of T cell function
reflects a dynamic metabolic status. mTOR, a key regulator of
T cell metabolism, is induced by TCR and co-stimulatory signals
downstream of the PI3K-Akt axis and serves to dynamically inte-
grate nutrient-sensing pathways with signaling pathways
involved in differentiation, growth, survival, and proliferation (Pol-
lizzi and Powell, 2014). Upon stimulation, conventional CD4+ and
CD8+ T cells utilize the mTOR pathway to meet the increased
metabolic demands of T cell activation by switching from primar-
ily oxidative phosphorylation, seen in resting T cells, toward a
state of enhanced aerobic glycolysis (Pollizzi and Powell,
2014). Of note, mTOR signaling also influences sterol meta-
bolism in T cells (Zeng et al., 2013). The importance of these phe-
nomena in determining T cell fate was first noticedwith the selec-
tive inhibitor of mTOR, rapamycin, which prevented the
generation of effector T cell responses and promoted the gener-
ation of Treg cells (Zheng et al., 2007). This is well illustrated by
studies of Treg cells, whose generation and homeostasis is a
complex and dynamic phenomenon tightly linked to both im-
mune signals and metabolic cues. The current dogma arising
from the literature is that specific T cell lineages have unique
metabolic profiles essential for their development and function.
Regarding Treg cells, it has been shown that lipid oxidation is
the key metabolic program sustaining their in vitro proliferation
and function (Michalek et al., 2011). However, in vivo data have
established that Treg cells exhibit higher glycolytic and prolifer-
ative rates than do their effector counterparts (Procaccini et al.,
2010). One could speculate that in vivo, immune cell differentia-
tion is a dynamic process regulated by several interrelated fac-
tors. In this sense, proper T cell activation, relying on several
oscillatory cues (such as TCR-signal strength, cytokine milieu,
and nutrient availability), specifically engages the opportune
metabolic programs required to ensure T cell activation on one
side and to drive Treg cell commitment to constrain the immune
responses on the other. In this context, dynamic and oscillatory
changes in mTOR activity seem to be crucial in Treg cell homeo-
stasis in vivo and in vitro, particularly in the context of their meta-428 Immunity 43, September 15, 2015 ª2015 Elsevier Inc.bolic regulation. mTOR activity in freshly isolated human Treg
cells, and the phosphorylation of mTOR, is significantly higher
in Treg cells than in CD4+CD25 effector T cells. Treg cell activity
was also studied with a novel approach whereby the mTOR
pathwaywas transiently inhibited in vitro with rapamycin (without
exogenous IL-2) prior to anti-CD3 and anti-CD28 stimulation.
Surprisingly, the acute or transient mTOR inhibition resulted in
the reversal of Treg cell anergy and robust proliferation. Whereas
both acute and chronic treatment with rapamycin reduced the
proliferation of effector T cells, the proliferation of Treg cells
did not occur with chronic rapamycin treatment in the absence
of exogenous recombinant IL-2 (Procaccini et al., 2010). Thus,
Treg cells appear more sensitive than effector T cells to short
and transient perturbation of the mTOR pathway. Of note, the
abrogation of Treg cell anergywith acute pretreatment with rapa-
mycin was associated with increased IL-2 production by Treg
cells and was reversed by the addition of an IL-2-neutralizing
antibody to the cultures, indicating IL-2 dependency. Taken
together, these data suggest that ‘‘oscillating’’ leptin or
nutrient-dependent mTOR activity might set the threshold for
responsiveness of Treg cells. It is possible that in vivo, a contin-
uous ‘‘oscillatory’’ change in mTOR activity depending on the
fluctuations in the composition of the extracellular milieu controls
the high proliferative rate of Treg cells in mice and humans.
Therefore, these data might have relevance in setting novel pro-
tocols to control autoimmunity and in vitro expansion of thera-
peutic Treg cells.
Emerging Targets for Metabolic Immunomodulation:
Toward Cell- and Function-Selective Reprogramming?
Recent discoveries have highlighted how metabolic configura-
tion can affect a number of key events in immune responses
other than cell division and differentiation. For example, aberrant
metabolism can affect epigenetic reprogramming of immune
cells, as well as autoimmunity; furthermore, cell metabolic prod-
ucts could act as immune signaling molecules. A better under-
standing of these processes might provide further avenues for
tissue-specific and/or cell-function-specific immunometabolic
targeting.
Epigenetic-Metabolic Reprogramming of Innate
Immune Cells
Epigenetic reprogramming of myeloid cells, also known as
trained immunity, representsade factomemoryof innate immune
responses and confers non-specific protection from secondary
infections (Netea et al., 2011). A key mechanism for the induction
of trained immunity in mammalian monocytes and macrophages
isepigenetic reprogrammingaccompaniedbychanges inhistone
marks, such as H3K4me1, H3K4me3, and H3K27Ac (Quintin
et al., 2012; Saeed et al., 2014). This process is responsible for
the increased responsesof the trainedcell for host defensegenes
upon restimulation with different stimuli. The critical set of genes
that are triggered upon induction of trained immunity includes
genes encoding glycolytic enzymes, suggesting a shift in cellular
metabolism of glucose. Indeed, trained monocytes display high
glucose consumption, high lactate production, and a high ratio
of nicotinamide adenine dinucleotide (NAD(+)) to its reduced
form (NADH), reflecting a shift in metabolism with an increase in
glycolysis dependent on the activation of mTOR through a dec-
tin-1-Akt-HIF-1a pathway. Inhibition of Akt, mTOR, or HIF-1a
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et al., 2014), indicating that metabolic reprogramming is a key
step for the induction of trained immunity. For the long-term
changes in themacrophage phenotype, the effect of Krebs cycle
metabolites (such as succinate and alpha-ketoglutarate) for inhi-
bition or induction of histone demethylases (such as JMJD3) or
the important role of NAD+ for the activity of the sirtuin class of de-
acetylases are examples of close interaction between cellular
metabolism and epigenetic reprogramming.
Given that epigenetic reprogramming of monocytes can be
initiated by microbial moietis (Quintin et al., 2012; Kleinnijenhuis
et al., 2012) and metabolites (Arts et al., 2015; Cheng et al.,
2014), it is possible that this event might contribute to (1) the
establishment of inflammation in obesity and atherosclerosis
and (2) the alteration of the gut microbiota, thus making this
aspect an intriguing target for therapeutic intervention. It remains
to be addressed whether therapeutic control of metabolic risk
factors in humans affect epigenetic reprogramming.
Metabolic Regulation of Immune Cell Trafficking
It is becoming increasingly clear that intermediate or end prod-
ucts of metabolic pathways not only function as feedback regu-
lators and provide substrates used by other pathways but also
can bind to cognate receptors to initiate de novo signaling cas-
cades. An obvious example is provided by the ability of products
of the gut microbiota to regulate systemicmetabolism. A number
of additional paradigms have recently emerged. The glycolysis
end product lactate, released by tumor cells, induces the con-
version of macrophages to tumor-associated macrophages
(TAMs), which show characteristics of M2 macrophages, via a
HIF-1a-mediated mechanism (Colegio et al., 2014). In T cells,
extracellular sodium lactate and lactic acid can selectively regu-
late multiple functions of CD4+ and CD8+ T cells, including traf-
ficking and retention in inflamed tissue, via subtype-specific
transporters Slc5a12 and Slc16a1, which are selectively ex-
pressed by CD4+ and CD8+ subsets, respectively, and inhibit
the glycolytic pathway (Haas et al., 2015).
Cytoskeletal rearrangements necessary formigrationareoneof
the most energy-consuming cellular processes (Bernstein and
Bamburg, 2003; Daniel et al., 1986). Despite the fact that migra-
tory events dominate during the lifespan of most T lymphocytes,
very little is known about the metabolic pathways supporting
T cell motility. Indirect evidence suggests that the metabolic sta-
tus can influence Tcell homingpatterns. Rapamycin-mediated in-
hibition ofmTOR causes effector T cells to re-express CD62L and
CCR7 and home to secondary lymphoid organs (SLOs), where
they are trapped away from target sites in the periphery (Finlay
and Cantrell, 2011; Sinclair et al., 2008). Therefore, rapamycin
can promote immunosuppression by redirecting effector T cells
fromperipheral tissues to SLOs. A direct contribution of themeta-
bolic machinery—and glycolysis in particular—to the modulation
of T cell motility and migration has recently become evident. For
example, CCL5-induced CCR5 signaling was shown to activate
the mTOR-4E-BP1 pathway to directly modulate mRNA transla-
tionand initiate thesynthesisof chemotaxis-relatedproteins inhu-
man T cells (Murooka et al., 2008), an event that was shown to be
dependent on glycolysis, AMPK signaling, and downstream sub-
strates ACC-1, PFKFB-2, and GSK-3b. In addition, the CCL19-
and S1P-mediated signals have been shown to inhibit basal
FAO, but not basal glycolysis, of human resting CD4+ effectormemory T cells (Taub et al., 2013). However, anti-TCR antibody
activation of memory T cells increased their chemotaxis to
CCL5, which was dependent predominantly on glycolysis rather
than FAO, suggesting that distinct metabolic pathways are
engaged by migratory signals depending on the T cell activation
status. Further, recent evidence has shown that murine CD4+
and CD8+ T cell migration is highly dependent on aerobic glycol-
ysis in vitro and in vivo (Haas et al., 2015). This new evidence
opens the way for function-selective (i.e., migration) targeting of
immune cells by metabolic manipulation. This approach might
provide the advantage of selectively affecting highly migratory
T cells, such as effector T cells, while sparing other populations.
Aberrant Metabolism and Autoimmunity
Dysfunctional T cell responses are a typical feature of autoimmu-
nity and associate with altered metabolic profiles in T cells from
murine models of autoimmune diseases (Nath et al., 2009). It has
been shown that T cell dysregulation associates with metabolic
alterations in several human autoimmune conditions, such as
MS and SLE. In MS subjects, increased levels of both glutamine
and glutamate have been described, and glutamate concentra-
tion correlates with disease severity (Sarchielli et al., 2003; Tisell
et al., 2013). This is an important cue, given that TCR engage-
ment of naive CD4+ T cells triggers rapid uptake of glutamine,
which relies on the amino acid transporters. Glutamine is criti-
cally required for naive CD4+ T cell differentiation toward Th1
and Th17 inflammatory T cells; when activated in glutamine-
free medium, naive CD4+ T cells display a severe defect in the
generation of both Th1 and Th17 cells. These findings are in
line with recent data suggesting that proliferation of Treg cells
is impaired in subjects with relapsing-remitting MS (RR-MS) as
a result of over-activation of the mTOR pathway associated
with reduced IL-2-R-STAT5 signaling (Carbone et al., 2014). A
recent report showed that glycolysis andmitochondrial oxidative
metabolism were elevated in CD4+ T cells from lupus-affected
mice, and inhibition of these pathways (with 2DG andmetformin,
respectively) reduced IFN-g production (Yin et al., 2015). Metfor-
min also restored defective IL-2 production by CD4+ T cells from
lupus-affected mice. In vivo, treatment with a combination of
metformin and 2DG normalized T cell metabolism and reversed
disease biomarkers. In addition, enhanced glycolysis and mito-
chondrial metabolism were observed in CD4+ T cells from SLE
patients and correlated with T cell activation status; their
elevated IFN-g production was reduced upon in vitro treatment
with metformin. Likewise, metformin has been also shown to
reduce Th17 cell response and attenuate disease severity in
experimental autoimmune encephalomyelitis (Nath et al.,
2009). Because proliferating CD4+ T cells and effector CD8+
T cells are highly reliant on glycolysis, this approach might lead
to non-specific immunosuppression. A potential alternative for
selective targeting of pathogenic T cells has been provided by
observations that these chronically activated lymphocytes in
lupus and graft-versus-host disease (GVHD) share several meta-
bolic features, including increased OXPHOS and depleted
antioxidants, such as glutathione, as a consequence of low
glycolytic activity (GSH) (Wahl et al., 2012). Bz-423 is a non-anxi-
olytic 1,4-benzodiazepine that targets the mitochondrial F1Fo
ATPase (Johnson et al., 2005), blocking respiratory-chain func-
tion and generating superoxide. Depletion of antioxidants in
pathogenic T cells renders them selectively susceptible toImmunity 43, September 15, 2015 ª2015 Elsevier Inc. 429
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reported that Bz-423 rescued mice from lethal GVHD while not
adversely affecting the repopulation of donor thymocytes, gran-
ulocytes, or lymphocytes (Gatza et al., 2011).
Concluding Remarks
Intense ongoing investigation of immune cell metabolism is
yielding an exponentially growing amount of information.
Although such information provides potential new tools for ther-
apeutic manipulation of the immune response, it also underlines
the complex integration of immune networks and systemic
metabolism. Although the modulation of immunometabolism
represents a new avenue for tackling several diseases, a trans-
versal expertise involving immunology, endocrinology, and lipi-
dology is required for successfully translating preclinical data
for the benefit of human health. To date, most investigations
have focused on glucosemetabolism and less on beta-oxidation
of lipids, and more studies are needed to integrate different
anabolic and catabolic aspects of glucose, protein, and lipid
metabolism in the context of the immune response.
Another major challenge in the field is to resolve the ‘‘big pic-
ture’’ of how a broad array of metabolic pathways differentially
integrate into the complexity and variety of immunological re-
sponses in health and disease. In other words, basic in vitro
studies or investigations in experimental models need to move
to the next level, i.e., human physiology, by capitalizing on the
treasure throve of basic information that can be obtained from
human pathology, as we have described here.
As a starting point, we need to develop standardized
techniques allowing assessment of the metabolism of patient-
derived immune cell populations. Retrospective review of the im-
mune alterations and the impact of traditional metabolic drugs
on inflammation in patients might help modeling the physiologic
integration of metabolism and immune function. In parallel,
increased understanding of the symbiotic regulation of systemic
metabolism by physiologic products of the gut microbiota and
the identification of differential metabolic programs operating
in distinct immune cell subsets and functions will deliver tools
for cell- and function-specific targeting—the ‘‘holy grail’’ of ther-
apeutic immunomanipulation.
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